Thrombocytopenia can be genetic. Inherited thrombocytopenias are a well-established group of disorders caused by mutations in genes that control how platelets are produced and released into the bloodstream. That said, most cases of low platelet counts are acquired, meaning they develop later in life from infections, immune conditions, medications, or other triggers. The inherited forms are rare enough that nearly half of people who have them go undiagnosed, often because their condition gets mistaken for something else.
What Inherited Thrombocytopenia Looks Like
The clinical picture varies enormously depending on which gene is affected. Some genetic forms cause severe bleeding that shows up in the first weeks of life. Others are so mild they go unnoticed into adulthood, only discovered incidentally on a routine blood test. The hallmark shared across all inherited forms is a chronically low platelet count that has been present for as long as anyone can document, with no prior record of normal levels.
Common symptoms include easy bruising, prolonged bleeding after cuts or dental work, heavy menstrual periods, and tiny red or purple spots on the skin called petechiae. In milder genetic forms, people may simply bruise more easily than average and never think much of it.
How Genetic Forms Differ From Immune-Related Low Platelets
The most frequent misdiagnosis for inherited thrombocytopenia is immune thrombocytopenia (ITP), a condition where the immune system destroys its own platelets. In one referral center’s review, about 14% of patients sent in with an ITP diagnosis turned out to have been misdiagnosed, and the most common actual diagnosis was an inherited platelet disorder, accounting for 10% of those cases.
This matters because the treatments are completely different. ITP is typically managed with immune-suppressing therapies, which do nothing for a genetic condition where the problem is faulty platelet production rather than platelet destruction. People with inherited thrombocytopenia who are mistakenly treated for ITP may undergo rounds of ineffective therapy, including steroids or even spleen removal, before anyone suspects a genetic cause.
A few red flags suggest the problem might be genetic rather than immune-related: the low count has been present since childhood, standard ITP treatments haven’t worked, there’s a family history of low platelets or easy bleeding, or the platelets are an unusual size under the microscope (abnormally large or abnormally small, depending on the mutation).
Key Genes and What They Do
More than 40 genes have been linked to inherited thrombocytopenia. They generally fall into three categories: those that affect only platelets, those tied to broader syndromes involving other organ systems, and those that raise the risk of blood cancers. A few of the most well-characterized examples help illustrate the range.
MYH9-Related Disease
Mutations in the MYH9 gene cause abnormally large platelets and a low platelet count. The gene encodes a protein essential for the final step of platelet production: megakaryocytes, the parent cells in bone marrow, need to extend long, thin protrusions that poke into blood vessels and shed platelets from their tips. When MYH9 is mutated, these protrusions form poorly, with less branching and oversized tips, so fewer platelets make it into the bloodstream and the ones that do are larger than normal. Some people with MYH9 mutations also develop kidney problems, hearing loss, or cataracts over time.
RUNX1 Familial Platelet Disorder
RUNX1 mutations cause mild to moderate thrombocytopenia with easy bruising, but the bigger concern is cancer risk. People who inherit a RUNX1 mutation have an estimated 20% to 50% lifetime risk of developing a blood cancer, most commonly acute myeloid leukemia or myelodysplastic syndrome. About 25% of affected families have at least one member who develops a lymphoid malignancy such as lymphoma or acute lymphoblastic leukemia. This makes genetic identification important not just for managing bleeding, but for cancer surveillance.
ETV6-Related Thrombocytopenia
ETV6 mutations produce a mild low platelet count that’s easy to overlook because the platelets are normal-sized, unlike many other inherited forms. Routine lab work doesn’t point to anything distinctive. However, several affected individuals have developed B-cell acute lymphoblastic leukemia during childhood at rates far above the general population, making this another form where knowing the genetic cause changes how the person is monitored.
Wiskott-Aldrich Syndrome
This X-linked condition almost exclusively affects males. Its signature is unusually small platelets combined with a low count, the opposite of what’s seen in MYH9 disease. Boys typically present early in life with bleeding, eczema, and recurrent infections due to immune deficiency. A milder variant, X-linked thrombocytopenia, causes primarily the small-platelet low count without the full immune and skin problems.
ANKRD26-Related Thrombocytopenia
Mutations in the regulatory region of ANKRD26 are one of the more common causes of inherited thrombocytopenia, though fewer than 200 affected individuals have been formally reported. The true number is likely higher because the condition was only recently described and can be difficult to diagnose. Like RUNX1 and ETV6 forms, it carries an increased risk of blood cancers.
When Genetic Testing Makes Sense
Genetic testing is typically considered when someone has unexplained chronic thrombocytopenia lasting more than a year, with no prior record of a normal platelet count, and at least one additional clue. Those clues include a family history of low platelets, failure to respond to standard ITP treatments, bleeding that seems out of proportion to the platelet count, abnormal platelet size or shape, abnormal platelet function on specialized tests, or physical features associated with known syndromes.
Testing usually involves a gene panel that screens dozens of known thrombocytopenia-related genes simultaneously. Even with current technology, roughly 50% of patients with suspected inherited thrombocytopenia still don’t get a definitive genetic answer, meaning there are mutations and genes yet to be discovered.
How Genetic Thrombocytopenia Is Managed
Treatment depends entirely on which gene is involved and how severe the bleeding tendency is. Many people with mild inherited forms need no routine treatment at all. They simply take precautions before surgery or dental procedures.
For those who do need treatment, medications that stimulate platelet production (thrombopoietin receptor agonists) have shown promise in certain genetic forms. Short courses of these drugs can raise platelet counts before planned surgeries in people with MYH9 disease and have been used as a bridge therapy in Wiskott-Aldrich syndrome patients awaiting bone marrow transplant. They’ve also been tried in ANKRD26-related thrombocytopenia. These drugs work best when the underlying problem involves defective platelet formation rather than a fundamentally different issue.
For severe forms like classic Wiskott-Aldrich syndrome, bone marrow transplant remains the only curative option, as it replaces the defective stem cells entirely. For forms carrying elevated cancer risk, like RUNX1 and ETV6 mutations, the most important intervention is long-term monitoring with regular blood counts to catch any malignant transformation early.
Inheritance Patterns Vary by Gene
Inherited thrombocytopenias follow different inheritance patterns depending on the gene. Many, including RUNX1, ETV6, MYH9, and ANKRD26 forms, are autosomal dominant, meaning a single copy of the mutated gene from one parent is enough to cause the condition. Each child of an affected parent has a 50% chance of inheriting the mutation. Wiskott-Aldrich syndrome is X-linked, so it primarily affects boys while mothers are typically carriers without symptoms. A smaller number of inherited forms follow an autosomal recessive pattern, requiring a mutated copy from both parents.
If you or a family member has been diagnosed with inherited thrombocytopenia, genetic counseling can clarify the specific inheritance pattern, the implications for other family members, and whether the particular mutation carries additional risks like cancer predisposition that would warrant closer surveillance.